

## The Global Challenge and Opportunity for Canadian Biotech


The world's population is predicted to grow to almost 10 billion people by 2050. This means drastic global changes in human health, the environment, food security and economic fortunes have already started to impact our day to day lives. Demands for consumer goods, healthcare, energy and western based diets emanating from ever increasing populations in countries such as China and India are impacting economies, human health, the environment, and food and water supply like never before.



## The Strength of Canada's Biotechnology Ecosystem


As a result of its history of scientific discovery and innovation, Canada is home to a strong network of biotech hubs in every region of the country. At the centre of those hubs are world class universities, hospitals and research institutions. These combine with a national network of incubators and accelerators, and hundreds of small start-up companies helping to draw biotechnology research into the development of innovative products.

Canada has a diverse biotech ecosystem with clusters in every province, in which small -and medium- sized biotech companies work with universities, research institutes and hospitals, regulatory authorities and multinationals to bring their innovations to market. Correspondingly the biotech ecosystem is well-positioned to be a major contributor to solutions for the challenges in agriculture, energy production, environmental remediation, industry and healthcare.





In just a few short years several early stage Canadian health biotech companies have grown rapidly and moved closer to becoming commercial reality. This group includes Aquinox Pharmaceuticals, Innovative Targeting Solutions, Xenon, Zymeworks, Northern Biologics, Clementia and Engene. All have moved from being theoretical concepts to companies on the brink of commercial reality who employ hundreds of highly educated individuals.



## Establishing a Vibrant and Competitive Ecosystem for Economic Growth

Importantly, in the health space, the pharma industry model for transforming innovation has evolved significantly over the past decade. Whereas, for many years discovery, research, development and manufacturing were all done in-house, the new pharmaceutical model is one of collaboration and partnership which brings the large multinational companies together with smaller companies, research institutions and technology incubators. Indeed, successful early stage Canadian biotech companies Aquinox, Xenon, Zymeworks, Northern Biologics and dozens of others, have all benefited from established partnerships and/or investments from multinational pharma or biotechnology companies.

In addition, the recently launched JLABS@Toronto represents a new form of economic cooperation which will support the development of more companies and entrepreneurs.



In few other countries would it have been possible to turn an idea like ours — nonbrowning Arctic® apple varieties that can reduce waste and boost consumption — into a reality. Canada's support for innovation and commitment to an evidence-based regulatory system are instrumental for small companies like ours to succeed. In an ever-evolving industry, support for sound biotech regulations and educational programs will be essential to assure Canadian innovation continues to thrive.

Neal Carter, President, Okanagan Specialty Fruits Inc.

As founding Director of BIOTECanada and leader of WinRho development, first approved in 1980, I have witnessed and participated in the incredible growth of the biotech industry with challenges and successes in the last fifty years. I believe that the biotech industry can and will play a most important role in Canada's future economic growth with a clear vision and focus on the B.E.S.T. (Business, Entrepreneurship, Science and Tenacity or perseverance) model.

Albert (Bert) D. Friesen PhD CEO, Medicure

At Northern Biologics, we're very proud to headquarter our global biotechnology company in Toronto. We're within walking distance of several top tier academic and clinical research institutes, and enjoy tremendous access to cutting edge science, dedicated clinicians, and a very large patient population. We've also had great success in recruiting US and European R&D leadership talent to Toronto to complement the existing talent pool of highly trained bench scientists.

Stefan Larson PhD CEO, Northern Biologics

The biggest challenge we had at QLT was bringing an awful lot of well-tutored in the pharmaceutical and biotech industry experts as senior scientists into Canada who were able to train up intelligent, educated locals. There is now a pool of those with manufacturing; drug development and clinical expertise who came out of QLT, and have offered their knowledge to benefit other biotech companies in Vancouver. There is a great model there.

Julia Levy, Founder QLT

## Access to Capital and Talent

Canada is in an enviable position globally. Home to a strong biotech ecosystem including a highly skilled workforce, hundreds of early stage companies, supportive university and health care systems, leading science and scientists, Canada is well-positioned to attract more investment, companies and people. Community and entrepreneurial spirit along with recent successes in the venture capital and public markets, have proven Canadian companies can attract hundreds of millions of dollars of investment. But attracting global investors and talent will always be a challenge as other countries aggressively pursue the same investors and talent for their domestic industry.

Capital investment is attracted by the caliber of scientific discovery, the people leading the development of that discovery, and by the conditions for how well treated the investment is offered. Other countries are developing their biotechnology sectors. While industry plays a lead role in attracting investment, government policy establishes the hosting conditions that attract capital.

While Canada's biotechnology sector has grown somewhat organically, governments play a key role in supporting the sector's ability to attract companies, talent and investment. In this regard, Canada has been very competitive by providing:

Fast, reliable and predictable regulatory system that relies on science-based decision making, up-to-date understanding of complex science and anticipation of new technologies.

Stable government with sound fiscal conditions.

Competitive corporate tax rate and fair tax policy, including programs such as SR&ED.

Intellectual property protections.

Supportive commercial environment with such programs as IRAP and the Venture Capita Catalyst Initiative.

 Strong provincial government economic development programs to grow SME companies.



